ALECENSA - alectinib hydrochloride capsule

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Nov '26

DSGNPhase 3$781M

ALECENSA - alectinib hydrochloride capsule Phase 3 Est. Readout

ALECENSA - alectinib hydrochloride capsule• ALK-Positive Non-Small Cell Lung Cancer (NSCLC)600

Nov 2026~Confirmed

00%

Competitive Landscape

0 competitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Drug Information

Target Indication

ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

DSGN

Design Therapeutics, Inc.

Related Pipeline

Friedreich Ataxia

Fuchs Endothelial Corneal Dystrophy

Sarcoma

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts